FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL	

OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address Salzmann Peter			2. Issuer Name and Ticker or Trading Symbol Immunovant, Inc. [IMVT]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
(Last) C/O IMMUNOVA	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 04/12/2023	X	Officer (give title below) Chief Executive Of	10% Owner Other (specify below)				
320 W 37TH STR (Street) NEW YORK	EET, 6TH FLOOR	10018	If Amendment, Date of Original Filed (Month/Day/Year) Constitution of Control o							
(City)	(State)	(Zip)	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.							

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution Date, Transacti			4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	Form: Direct (D)	Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock ⁽¹⁾	04/12/2023		A		243,832(2)	A	\$0	1,237,764	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Deriv	urity (Instr.	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (In 8)		5. Number Derivative Securities Acquired Disposed (Instr. 3, 4	e s (A) or l of (D)		ate	7. Title and Ar Securities Un Derivative Sec 3 and 4)	derlying	8. Price of Derivative Security (Instr. 5)	Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
	k Option at to buy)	\$14.7	04/12/2023		A		316,585		(3)	04/12/2033	Common Stock	316,585	\$0	316,585	D	

Explanation of Responses:

- 1. Represents the number of shares underlying restricted stock units awards ("RSUs").
- 2. The RSUs vest over four years, with 25% of the RSUs vesting on April 12, 2024 and the remainder of the RSUs vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.
- 3. Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on April 12, 2024 and the remainder of the shares underlying the options vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

Remarks:

/s/ Eva Renee Barnett, attorney-in-04/14/2023 fact for Peter Salzmann

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.